final os findings of zolbetuximab and folfox6 in the spotlight trial
Published 4 months ago • 102 plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
2:49
spotlight: zolbetuximab and m-folfox6 in cldn18.2 , her2- gej cancer
-
6:39
spotlight: final os results for zolbetuximab plus mfolfox6 in metastatic gastric/gej adenocarcinoma
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
2:17
claudin 18.2 and fgfr2b as novel targets in gastric cancer
-
3:34
flow spotlight: addressing nausea vomiting in gastric cancer treatment with 1l zolbetuximab
-
2:56
will zolbetuximab impact the treatment landscape for gastric cancer?
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
1:52
iilustro: zolbetuximab, mfolfox6, and nivolumab combinations for gastrointestinal cancer
-
43:59
34 first line therapy for her2- pdl1- cldn18.2 gea
-
12:03
asco 2024 - michael petroutsas
-
3:40
公开化疗的诊疗步骤全过程！第一次化疗治疗指南
-
1:04
dr. ilson on the utility of zolbetuximab in claudin-positive gastric cancers
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
0:42
evaluating patient suitability for zolbetuximab in gastroesophageal cancer
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
2:09
recent advances in gastrointestinal research: destiny-gastric01 and spotlight
-
7:46
results from the phase 2 fast study of astellas’ investigational zolbetuximab
-
2:30
final os results of imvigor130: atezolizumab plus platinum/gemcitabine for muc
-
1:28
highlights in gastric and colorectal cancer at asco gi 2023
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
15:58
chemotherapy in gastric cancer & esophageal cancer - basis, magic trial, flot trial, cross protocol
-
10:01
how astellas is forging a path in gastric cancer through its commitment to targeted research